Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes

Area of Science:

• Cardiology
• Endocrinology
• Molecular Biology

Background:

• Diabetic cardiomyopathy (DCM) is a distinct cardiac complication in diabetes mellitus.
• DCM presents initially with diastolic dysfunction and progresses to heart failure (HF) independent of other cardiovascular risk factors.
• Diabetes mellitus is a complex, multifactorial disease influenced by genetic and environmental factors, with epigenetics emerging as a significant contributor.

Purpose of the Study:

• To review the current understanding of epigenetic mechanisms in the pathogenesis of diabetic cardiomyopathy.
• To highlight the roles of DNA methylation, histone modifications, and non-coding RNAs in DCM.
• To explore the potential of epigenetic modifications as therapeutic and preventive targets for DCM.

Main Methods:

• Literature review of recent studies on epigenetics and diabetic cardiomyopathy.
• Analysis of established and emerging epigenetic mechanisms involved in DCM.
• Synthesis of current knowledge on the impact of epigenetics on cardiac function in diabetes.

Main Results:

• Epigenetic mechanisms, including DNA methylation, histone modifications, and non-coding RNAs, are implicated in DCM development.
• These epigenetic alterations can directly or indirectly influence cardiac structure and function in diabetic individuals.
• While recognized as key players, the precise impact of all epigenetic modifications in DCM remains incompletely understood.

Conclusions:

• Epigenetic dysregulation is a critical factor in the pathogenesis of diabetic cardiomyopathy.
• Further research into epigenetic mechanisms offers promising avenues for novel therapeutic and preventive strategies for DCM.
• Understanding the intricate roles of epigenetics in DCM is essential for improving outcomes in diabetic populations.